- Home
- IXHL vs TCRX Comparison
IXHL vs TCRX Comparison
Compare IXHL & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IXHL
- TCRX
- Stock Information
- Founded
- IXHL 2001
- TCRX 2018
- Country
- IXHL Australia
- TCRX United States
- Employees
- IXHL N/A
- TCRX N/A
- Industry
- IXHL
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- IXHL
- TCRX Health Care
- Exchange
- IXHL Nasdaq
- TCRX Nasdaq
- Market Cap
- IXHL 78.7M
- TCRX 82.1M
- IPO Year
- IXHL N/A
- TCRX 2021
- Fundamental
- Price
- IXHL $1.05
- TCRX $1.93
- Analyst Decision
- IXHL
- TCRX Strong Buy
- Analyst Count
- IXHL 0
- TCRX 6
- Target Price
- IXHL N/A
- TCRX $9.50
- AVG Volume (30 Days)
- IXHL 163.0M
- TCRX 572.1K
- Earning Date
- IXHL 05-15-2025
- TCRX 08-11-2025
- Dividend Yield
- IXHL N/A
- TCRX N/A
- EPS Growth
- IXHL N/A
- TCRX N/A
- EPS
- IXHL N/A
- TCRX N/A
- Revenue
- IXHL $98,000.00
- TCRX $4,421,000.00
- Revenue This Year
- IXHL $2,538.49
- TCRX $159.20
- Revenue Next Year
- IXHL $249.95
- TCRX N/A
- P/E Ratio
- IXHL N/A
- TCRX N/A
- Revenue Growth
- IXHL N/A
- TCRX N/A
- 52 Week Low
- IXHL $0.08
- TCRX $1.02
- 52 Week High
- IXHL $3.12
- TCRX $7.44
- Technical
- Relative Strength Index (RSI)
- IXHL 65.21
- TCRX 63.03
- Support Level
- IXHL $0.21
- TCRX $1.75
- Resistance Level
- IXHL $1.66
- TCRX $1.96
- Average True Range (ATR)
- IXHL 0.15
- TCRX 0.14
- MACD
- IXHL 0.11
- TCRX 0.01
- Stochastic Oscillator
- IXHL 57.99
- TCRX 94.00
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.